<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29850" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperthyroidism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mathew</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>St. Luke's at Des Peres Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaur</surname>
            <given-names>Jasleen</given-names>
          </name>
          <aff>HealthPartners, Minneapolis</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rawla</surname>
            <given-names>Prashanth</given-names>
          </name>
          <aff>Sovah Health, Martinsville, VA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Mathew declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jasleen Kaur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prashanth Rawla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29850.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hyperthyroidism is a common thyroid disorder with multiple underlying etiologies. This disease is characterized by excess thyroid hormone production. Hyperthyroidism can be overt or subclinical. Overt hyperthyroidism is defined as low or suppressed thyroid stimulating hormone (TSH) levels with elevated triiodothyronine (T3) levels and/or elevated thyroxine (T4) levels. Hyperthyroidism is associated with significant short-term and long-term morbidity. Therefore, early recognition of this condition and timely instruction of appropriate therapy is critical. This activity reviews the etiology, presentation, evaluation, and management of hyperthyroidism and reviews the role of the interprofessional team in evaluating, diagnosing, and managing the condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the various etiologies that lead to a presentation of hyperthyroidism.</p></list-item><list-item><p>Describe the presentation and expected examination findings when evaluating a patient with hyperthyroidism.</p></list-item><list-item><p>Summarize the various treatment options available for hyperthyroidism, depending on specific etiology.</p></list-item><list-item><p>Explain the importance of interprofessional team strategies for improving care coordination and communication to aid in prompt diagnosis of hyperthyroidism and improving outcomes in patients diagnosed with the condition.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29850&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29850">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29850.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperthyroidism is a common thyroid disorder. "Hyperthyroidism" defines a syndrome associated with excess thyroid hormone production.<xref ref-type="bibr" rid="article-29850.r1">[1]</xref> It is a common misconception that the terms thyrotoxicosis and hyperthyroidism are synonyms. The term "thyrotoxicosis" refers to a state of excess thyroid hormone exposure to tissues.<xref ref-type="bibr" rid="article-29850.r1">[1]</xref>&#x000a0;Although hyperthyroidism can lead to thyrotoxicosis and can be used interchangeably, it is essential to note their differences. For the sake of simplicity, this review will cover a discussion of hyperthyroidism and thyrotoxicosis. Hyperthyroidism has multiple etiologies, clinical manifestations, and treatment modalities.</p>
        <p>Hyperthyroidism can be overt or subclinical. Overt hyperthyroidism is defined as low or suppressed thyroid stimulating hormone (TSH) levels with elevated triiodothyronine (T3) levels and/or elevated thyroxine (T4) levels.<xref ref-type="bibr" rid="article-29850.r1">[1]</xref> When T3 levels are elevated with low/suppressed TSH and normal T4 levels, this is called 'T3 toxicosis'.<xref ref-type="bibr" rid="article-29850.r2">[2]</xref> Subclinical hyperthyroidism is low or suppressed TSH with normal T3 and T4 levels.<xref ref-type="bibr" rid="article-29850.r2">[2]</xref> Both overt and subclinical hyperthyroidism are associated with significant long-term complications.<xref ref-type="bibr" rid="article-29850.r3">[3]</xref><xref ref-type="bibr" rid="article-29850.r4">[4]</xref><xref ref-type="bibr" rid="article-29850.r5">[5]</xref><xref ref-type="bibr" rid="article-29850.r6">[6]</xref><xref ref-type="bibr" rid="article-29850.r7">[7]</xref></p>
      </sec>
      <sec id="article-29850.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The three most common etiologies of hyperthyroidism include:</p>
        <list list-type="order">
          <list-item>
            <p>Graves disease (GD)</p>
          </list-item>
          <list-item>
            <p>Toxic multinodular goiter (TMNG)</p>
          </list-item>
          <list-item>
            <p>Toxic adenoma (TA)<xref ref-type="bibr" rid="article-29850.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Other less common etiologies of hyperthyroidism:</p>
        <list list-type="order">
          <list-item>
            <p>Iodine-induced hyperthyroidism<xref ref-type="bibr" rid="article-29850.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>TSH (thyroid stimulating hormone)-secreting pituitary adenomas<xref ref-type="bibr" rid="article-29850.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Conditions associated with high human chorionic gonadotrophin levels: choriocarcinomas and hydatiform moles in females and germ cell tumors in males<xref ref-type="bibr" rid="article-29850.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Ectopic thyroid in struma ovarii (excess thyroid hormone production from ovarian teratomas)<xref ref-type="bibr" rid="article-29850.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Extensive metastasis from functionally differentiated thyroid carcinoma (follicular or papillary)<xref ref-type="bibr" rid="article-29850.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Drug-induced thyroiditis: amiodarone, lithium, tyrosine kinase inhibitors, interferon-alpha, immune checkpoint inhibitor therapy<xref ref-type="bibr" rid="article-29850.r13">[13]</xref><xref ref-type="bibr" rid="article-29850.r14">[14]</xref><xref ref-type="bibr" rid="article-29850.r15">[15]</xref><xref ref-type="bibr" rid="article-29850.r16">[16]</xref><xref ref-type="bibr" rid="article-29850.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Other thyroiditis: Hashitoxicosis, painless thyroiditis, painful subacute thyroiditis, suppurative thyroiditis, and Riedel thyroiditis<xref ref-type="bibr" rid="article-29850.r18">[18]</xref><xref ref-type="bibr" rid="article-29850.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Factitious thyroiditis (due to excess exogenous thyroid hormone: intentional or unintentional use)<xref ref-type="bibr" rid="article-29850.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>Graves disease is the most common cause of hyperthyroidism in the United States and most Western countries.<xref ref-type="bibr" rid="article-29850.r20">[20]</xref> As Graves disease is autoimmune in etiology, this form of hyperthyroidism tends to manifest itself in younger populations. In older adults and people living in regions of iodine deficiency, toxic multinodular goiter is the most common cause of hyperthyroidism.<xref ref-type="bibr" rid="article-29850.r21">[21]</xref><xref ref-type="bibr" rid="article-29850.r22">[22]</xref><xref ref-type="bibr" rid="article-29850.r23">[23]</xref></p>
        <p>Factitious thyroiditis&#x000a0;is&#x000a0;thyrotoxicosis&#x000a0;associated with inappropriate or excessive use of pharmaceutical thyroid hormone.<xref ref-type="bibr" rid="article-29850.r10">[10]</xref> Due to a well-received side effect of weight loss, thyroxine has the potential for abuse. Any history of a hyperthyroid patient should include a medication list and an assessment of possible misuse (whether intentional or unintentional).</p>
      </sec>
      <sec id="article-29850.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of hyperthyroidism&#x000a0;varies worldwide, based on dietary iodine content.<xref ref-type="bibr" rid="article-29850.r12">[12]</xref>&#x000a0;Hyperthyroidism is more common in women compared to men.<xref ref-type="bibr" rid="article-29850.r24">[24]</xref>&#x000a0;Other risk factors associated with the development of hyperthyroidism include smoking, iodine deficiency, iodine excess, selenium deficiency, genetic factors, and the use of certain drugs.<xref ref-type="bibr" rid="article-29850.r12">[12]</xref>&#x000a0;Graves disease is typically seen in younger patients and is the most common cause of hyperthyroidism in this demographic. The incidence of GD is highest between the age group of 30 to 50 years.<xref ref-type="bibr" rid="article-29850.r25">[25]</xref> Toxic multifocal goiter is typically seen in older individuals and is the most common cause of hyperthyroidism in this demographic.<xref ref-type="bibr" rid="article-29850.r22">[22]</xref>&#x000a0;Graves disease and toxic multifocal goiter have a female predilection and are typically seen in patients with pertinent family and personal medical histories. Thyroid nodular disease is also more common in women&#x000a0;than men by 5- to 15-fold.<xref ref-type="bibr" rid="article-29850.r26">[26]</xref> Autoimmune thyroid disorders like Graves disease are more common in iodine-replete areas, and nodular thyroid diseases are more common in iodine-deficient areas.<xref ref-type="bibr" rid="article-29850.r12">[12]</xref></p>
        <p>The 1977 Whickham Survey evaluated the spectrum of thyroid disorders in County Durham in northeastern England. The Whickham Survey demonstrated a prevalence of hyperthyroidism in women, approximately ten times more than that of men (2.7% versus 0.23%).<xref ref-type="bibr" rid="article-29850.r27">[27]</xref>&#x000a0;An incidence of 80 cases per 100,000 women was seen at the 20-year follow-up of the Whickham cohort.<xref ref-type="bibr" rid="article-29850.r28">[28]</xref>&#x000a0;The prevalence of hyperthyroidism in the United States was 1.3% in the general population, with 0.5% cases of overt hyperthyroidism and 0.7% cases of subclinical hyperthyroidism.<xref ref-type="bibr" rid="article-29850.r29">[29]</xref>&#x000a0;A meta-analysis found the prevalence of hyperthyroidism in Europe to be 0.75%.<xref ref-type="bibr" rid="article-29850.r24">[24]</xref>&#x000a0;The prevalence of overt hyperthyroidism is similar in China at 0.78%.<xref ref-type="bibr" rid="article-29850.r30">[30]</xref>&#x000a0;</p>
        <p>Amiodarone-induced thyrotoxicosis (AIT) is seen in about 6% of the individuals taking the medication in iodine-sufficient areas and about 10% in individuals taking the medication from iodine-deficient areas.<xref ref-type="bibr" rid="article-29850.r31">[31]</xref><xref ref-type="bibr" rid="article-29850.r32">[32]</xref></p>
      </sec>
      <sec id="article-29850.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of hyperthyroidism depends on the particular variant of hyperthyroidism.</p>
        <p>
<bold>Graves Disease</bold>
</p>
        <p>This is an autoimmune process&#x000a0;with antibodies against the TSH receptor. An interplay between genetic and environmental factors influences this autoimmune process. The antibodies stimulate the TSH receptor (TSHR), leading to increased production and release of thyroid hormones. The trophic effects on the thyroid also lead to the growth of the thyroid gland.<xref ref-type="bibr" rid="article-29850.r20">[20]</xref>&#x000a0;</p>
        <p>
<bold>Toxic Multinodular Goiter</bold>
</p>
        <p>Pathogenesis of TMNG includes the initial phase of development of the nodular disease. This phase is prolonged and present for years before the nodules develop autonomy for thyroid hormone production. The somatic mutations involving the TSHR lead to constitutive activation of the cAMP signaling pathway, resulting the thyroid autonomy.<xref ref-type="bibr" rid="article-29850.r33">[33]</xref>&#x000a0;There is a correlation between the size of the nodules and the development of hyperthyroidism. In a previous study, about 93.7% of the patients who developed overt hyperthyroidism had a nodule size greater than 3 cm.<xref ref-type="bibr" rid="article-29850.r34">[34]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Toxic Adenoma</bold>
</p>
        <p>These are solitary nodules with autonomous thyroid hormone production due to&#x000a0;somatic mutations in the TSHR</p>
        <p>
<bold>Iodine-Induced Hyperthyroidism (Jod-Basedow Phenomenon)</bold>
</p>
        <p>This is typically iatrogenic, resulting from excessive iodine intake through diet or administration of iodine-containing medications such as contrast media or amiodarone.<xref ref-type="bibr" rid="article-29850.r35">[35]</xref><xref ref-type="bibr" rid="article-29850.r36">[36]</xref> Individuals susceptible to this phenomenon include the ones residing in iodine-deficient regions, individuals with underlying thyroid nodular disease, or underlying occult GD or previously treated GD.<xref ref-type="bibr" rid="article-29850.r8">[8]</xref>&#x000a0;Hyperthyroidism develops about 2-12 weeks after exposure to excessive iodine.<xref ref-type="bibr" rid="article-29850.r37">[37]</xref> As mentioned previously, the organification of iodide residues into precursor thyroid hormone molecules is relatively self-regulating. Excessive circulating iodide inhibits organification, a process known as the Wolff-Chaikoff effect.&#x000a0;This autoregulation is escaped in the Jod-Basedow phenomenon leading to excess thyroid hormone in the presence of excess iodine/iodide.</p>
        <p>
<bold>Amiodarone-Induced Thyrotoxicosis</bold>
</p>
        <p>There are two subtypes of amiodarone-induced thyrotoxicosis (AIT):&#x000a0;type 1 and type 2. Type 1 AIT leads to increased thyroid hormone production secondary to excess iodine exposure from amiodarone in the setting of pre-existing thyroid disease (as seen in the Jod-Basedow phenomenon).<xref ref-type="bibr" rid="article-29850.r38">[38]</xref> The pre-existing thyroid disease is usually multinodular goiter or latent Graves disease. Type 2 AIT is destructive thyroiditis due to the direct toxic effects of amiodarone on the thyroid follicular cells.<xref ref-type="bibr" rid="article-29850.r39">[39]</xref></p>
        <p><bold>Thyroiditis</bold> results in the transient increase in circulating thyroid hormone resulting from&#x000a0;inflammation or destruction of the thyroid follicular cells. Various etiologies of thyroiditis have this common pathophysiology but vary in their clinical presentations. The inflammation or destruction of the thyroid follicular cells can result from autoimmunity (Hashimoto's thyroiditis, painless sporadic thyroiditis, and painless postpartum thyroiditis) or&#x000a0;the result of external factors (infections in painful subacute thyroiditis, suppurative thyroiditis, drug-induced thyroiditis).<xref ref-type="bibr" rid="article-29850.r19">[19]</xref></p>
      </sec>
      <sec id="article-29850.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Thyroid hormone has physiological effects on multiple organ systems. As a result, the symptoms and signs of hyperthyroidism involve manifestations from multiple organ systems. Clinical manifestations are associated with a hyperadrenergic and hypermetabolic state. Common manifestations include unintentional weight loss (about 10% of patients can gain weight due to increased appetite), palpitations, tremors, heat intolerance, dyspnea on exertion, increased anxiety, irritability, fatigue, muscle weakness, increased frequency of bowel movements (some patients can have significant diarrhea), hair loss, loss of libido, and oligomenorrhea or amenorrhea in women.<xref ref-type="bibr" rid="article-29850.r20">[20]</xref><xref ref-type="bibr" rid="article-29850.r40">[40]</xref>&#x000a0;</p>
        <p>Patients with subacute thyroiditis can present with significant anterior neck pain and fever. On physical examination, patients have tachycardia (some can present with atrial fibrillation), hypertension, tremors, warm and moist skin, hyperreflexia, and an anxious appearance. Some patients might have signs of heart failure.</p>
        <p>Eye&#x000a0;signs of lid lad or lid retraction can be seen in all causes of hyperthyroidism due to a hyperadrenergic state.<xref ref-type="bibr" rid="article-29850.r41">[41]</xref> Eye symptoms and signs of "true orbitopathy' are only seen in patients with Graves disease. These include diplopia, excessive tearing, conjunctival injection, and orbital or retro-orbital pressure proptosis.<xref ref-type="bibr" rid="article-29850.r42">[42]</xref><xref ref-type="bibr" rid="article-29850.r43">[43]</xref> Other specific physical findings associated with Graves disease are pretibial myxedema (plaques of thick, scaly skin and swelling involving the anterior aspect of lower legs)&#x000a0;and acropachy (soft-tissue swelling of the hands and clubbing of the fingers).<xref ref-type="bibr" rid="article-29850.r44">[44]</xref><xref ref-type="bibr" rid="article-29850.r45">[45]</xref><xref ref-type="bibr" rid="article-29850.r46">[46]</xref></p>
        <p>Examining&#x000a0;the thyroid will reveal a diffuse non-nodular enlargement of the thyroid in Graves disease; a diffuse non-symmetric nodular enlargement can be seen in toxic multinodular goiter, and a single large nodule can be palpated in cases of a toxic adenoma. An exquisitely tender thyroid can be noted in subacute thyroiditis.<xref ref-type="bibr" rid="article-29850.r47">[47]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29850.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When hyperthyroidism is suspected based on clinical features, the patient should undergo an initial evaluation with measurement of TSH, free T4, and total T3 to confirm the diagnosis (see <bold>Figure.</bold> Evaluation Algorithm, Hyperthyroidism).&#x000a0;The figure&#x000a0;illustrates the diagnostic algorithm for hyperthyroidism. Patients with overt hyperthyroidism will have low/suppressed TSH levels with elevated free T4 and total T3 levels. Patients with mild/subclinical hyperthyroidism will have low/suppressed TSH with normal free T4 and total T3 levels. 'T3 toxicosis' is defined as low/suppressed TSH with normal T4 and elevated T3 levels.</p>
        <p>Conditions that can interfere with the assessment of TSH include the presence of heterophile antibodies and high biotin intake due to interference with the assays.<xref ref-type="bibr" rid="article-29850.r48">[48]</xref>&#x000a0;Heterophile antibodies can lead to a false elevation in TSH levels. High-dose biotin supplementation (5 to 30 mg) can result in falsely low TSH with elevated free T4 levels in vitro.<xref ref-type="bibr" rid="article-29850.r49">[49]</xref></p>
        <p>After the diagnosis of hyperthyroidism has been confirmed, measurement of thyrotropin receptor antibody (TRAb) levels as an initial test for determining the etiology of hyperthyroidism has been shown to reduce the time to diagnosis and is more cost-effective.<xref ref-type="bibr" rid="article-29850.r50">[50]</xref>. Elevated TRAb levels confirm the diagnosis of Graves disease. TRAb levels are measured using&#x000a0;TBI or TBII (thyrotropin-binding inhibiting or thyrotropin-binding inhibitory immunoglobulin) assays and TSI (thyroid stimulating immunoglobulin) bioassays. The newer bioassay using the Immulite method for TSI measurement has a high sensitivity and specificity of 98% and 99.9%, respectively, for diagnosing GD.<xref ref-type="bibr" rid="article-29850.r51">[51]</xref>&#x000a0;TBII assays used for measuring TRAb levels also have a high sensitivity of 96-97% and specificity of 99% of the diagnosis of GD.<xref ref-type="bibr" rid="article-29850.r52">[52]</xref></p>
        <p>If TRAb levels are normal, the patient should undergo a radioiodine thyroid uptake and scan using an I-123 isotope (enters the thyroid gland through the Na/I symporter). This test is contraindicated in pregnant and lactating women. A capsule containing an I-123 isotope is given a day before the scan is performed. The pattern of uptake of I-123 by the thyroid gland seen on the scan can help determine the diagnosis (see Figure 1). However, this test does not help differentiate between type 1 and type 2 amiodarone-induced thyrotoxicosis, as the uptake will be low in chronic amiodarone use.</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>High Uptake/Normal</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Graves disease will have high or normal uptake in a diffuse pattern</p>
              </list-item>
              <list-item>
                <p>TMNG will have a high or normal uptake in a patch pattern</p>
              </list-item>
              <list-item>
                <p>TA will have a high or normal uptake with a solitary area of high uptake (corresponding to the known nodule) with low uptake in the remainder of the gland</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>
<bold>Low or Absent Uptake</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Any etiology of thyroiditis is associated with low or absent uptake (Na/I symporters are not functional in inflamed or destroyed thyroid follicular cells)</p>
              </list-item>
              <list-item>
                <p>Iatrogenic and factitious thyrotoxicosis</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Thyroid ultrasound using the color Doppler is another important test that can help determine the underlying etiology. Intrathyroidal arterial flow velocities are measured.<xref ref-type="bibr" rid="article-29850.r53">[53]</xref>&#x000a0;Increased (thyroid inferno) and normal flow are seen in Graves disease. Low flow is seen in thyroiditis.<xref ref-type="bibr" rid="article-29850.r53">[53]</xref>&#x000a0;This test can help differentiate between type 1 and type 2 amiodarone-induced thyrotoxicosis (AIT). The flow will be high or normal in type 1 AIT (hyperthyroidism due to underlying nodular thyroid disease or occult GD) and low in type 2 AIT (destructive thyroiditis).<xref ref-type="bibr" rid="article-29850.r54">[54]</xref></p>
      </sec>
      <sec id="article-29850.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of hyperthyroidism depends on the underlying etiology and can be divided into symptomatic and definitive therapy. The symptoms of hyperthyroidism, such as palpitations, anxiety, and tremor, can be controlled with a beta-adrenergic antagonist such as atenolol. Calcium channel blockers, such as verapamil, can be used as second-line therapy for patients who are beta-blocker intolerant or have contraindications to beta-blocker treatment.<xref ref-type="bibr" rid="article-29850.r1">[1]</xref></p>
        <p>This review will only discuss the treatment for the most common causes of hyperthyroidism: Graves disease, toxic multinodular goiter, and toxic adenoma in non-pregnant patients.&#x000a0;</p>
        <p>Indications for treatment:</p>
        <list list-type="order">
          <list-item>
            <p>Overt hyperthyroidism</p>
          </list-item>
          <list-item>
            <p>Subclinical hyperthyroidism with TSH &#x0003c;0.1 and age &#x0003e;65 years</p>
          </list-item>
          <list-item>
            <p>Subclinical hyperthyroidism with TSH &#x0003c;0.1 and age &#x0003c;65 years with comorbidities (cardiovascular disease, osteoporosis, or symptomatic)</p>
          </list-item>
          <list-item>
            <p>Subclinical hyperthyroidism with TSH &#x0003c;0.1 and age &#x0003c;65 years, if TSH still elevated after 3&#x000a0;to 6 months</p>
          </list-item>
          <list-item>
            <p>Subclinical hyperthyroidism with TSH between 0.1-0.4 and age &#x0003e;65 years, if TSH still elevated after 3&#x000a0;to 6 months</p>
          </list-item>
          <list-item>
            <p>Subclinical hyperthyroidism with TSH between 0.1-0.4 and age &#x0003c;65 years with comorbidities (cardiovascular disease, osteoporosis, or symptomatic), if TSH still elevated after 3-6 months</p>
          </list-item>
        </list>
        <p>There are three definitive treatments for hyperthyroidism: radioactive iodine therapy (RAI), thionamide therapy, and subtotal thyroidectomy.&#x000a0;The choice of which definitive treatment modality depends on the etiology, comorbidities, and patient preferences.&#x000a0;Historically, radioactive iodine (RAI) has been the preferred treatment for managing Graves disease in the United States. Still, the trend is changing towards increased use of anti-thyroidal drugs (ATD).<xref ref-type="bibr" rid="article-29850.r55">[55]</xref>&#x000a0;ATDs have been the preferred treatment for Graves disease in most other countries.<xref ref-type="bibr" rid="article-29850.r1">[1]</xref>&#x000a0;</p>
        <p>
<bold>Antithyroid Drugs (ATDs)</bold>
</p>
        <p>Thionamide drugs include methimazole, carbimazole (precursor of methimazole), and propylthiouracil. These drugs are competitive inhibitors of the thyroid peroxidase (TPO) enzyme, resulting in their ability to block thyroid hormone synthesis. Additionally, these drugs may have additional immunosuppressive effects, as shown by their ability to induce remission in patients with Graves disease.<xref ref-type="bibr" rid="article-29850.r56">[56]</xref><xref ref-type="bibr" rid="article-29850.r57">[57]</xref>&#x000a0;Methimazole and propylthiouracil both inhibit thyroid hormone synthesis by thyroid peroxidase. Thyroid peroxidase is the enzyme responsible for converting dietary iodine into iodide. Propylthiouracil (PTU) also lowers peripheral tissue exposure to active thyroid hormone by blocking the extrathyroidal conversion of T4 to T3. Thionamide therapy has no permanent effect on thyroid function, and recurrence of hyperthyroidism is common in patients who discontinue thionamide therapy.</p>
        <p>Attaining a euthyroid status typically requires several months after initiation of thionamide therapy. Although methimazole and PTU are equally effective, methimazole is preferred due to once-daily dosing and a relatively better safety profile. An exception to this recommendation is in pregnant patients, in which PTU is preferred. Methimazole is associated with an increased risk of congenital defects, and thus PTU is preferred in managing hyperthyroidism during pregnancy.</p>
        <list list-type="bullet">
          <list-item>
            <p>Doses:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>ATA (Americal Thyroid Association) guidelines provide a rough guide for the initial dose of methimazole based on free T4 levels&#x000a0;<xref ref-type="bibr" rid="article-29850.r1">[1]</xref></p>
              </list-item>
              <list-item>
                <list list-type="bullet">
                  <list-item>
                    <p>Free T4 1-1.5 times upper limit of normal: Start methimazole 5-10 mg daily</p>
                  </list-item>
                  <list-item>
                    <p>Free T4 1.5-2.0 times the upper limit of normal: Start methimazole 10-20 mg daily</p>
                  </list-item>
                  <list-item>
                    <p>Free T4 2.0-3.0 times the upper limit of normal: Start methimazole 30-40 mg daily</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>PTU is administered in 2-3 doses per day due to its shorter duration of action. The initial dose of 5-150 three times daily is chosen based on the severity of hyperthyroidism. Once the disease is controlled, the dose can be decreased to a maintenance dose of 50 mg 2 to 3 times daily.</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Monitoring: TSH levels remain suppressed for almost six months in patients with Graves disease, so evaluation of free T4 and/or total T3 levels should be done every 4 to 6 weeks.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pregnancy: Propylthiouracil is the preferred drug in the first trimester, associated with lower incidence and severity of embryopathy than methimazole.<xref ref-type="bibr" rid="article-29850.r58">[58]</xref><xref ref-type="bibr" rid="article-29850.r59">[59]</xref>&#x000a0;The treatment can be switched to methimazole after 16 weeks of gestation.</p>
          </list-item>
          <list-item>
            <p>Drug conversions:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>10 mg of carbimazole is converted to approximately 6 mg of methimazole&#x000a0;<xref ref-type="bibr" rid="article-29850.r1">[1]</xref></p>
              </list-item>
              <list-item>
                <p>An equivalent dosage ratio of propylthiouracil to methimazole is 20:1. This ratio is recommended for dose conversions when switching between these agents.<xref ref-type="bibr" rid="article-29850.r60">[60]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>These drugs should be continued for at least 12-18 months. TRAb should be assessed at that time to evaluate for remission. If TRAb levels are normal, then thionamide therapy can be discontinued. If TRAb levels are still elevated, the patient remains at high risk for relapse if medication is stopped. Other factors associated with lower remission rates: male gender, smoking, large goiters, higher TRAb titers at the time of diagnosis, presence of orbitopathy, and the need for a high dose of thionamides to maintain euthyroidism.<xref ref-type="bibr" rid="article-29850.r20">[20]</xref></p>
        <p>An older study from the United States showed a 20-30% remission rate for Graves disease using thionamides.<xref ref-type="bibr" rid="article-29850.r61">[61]</xref>&#x000a0;European and Japanese populations noted higher remission rates of 50-60%.<xref ref-type="bibr" rid="article-29850.r62">[62]</xref><xref ref-type="bibr" rid="article-29850.r63">[63]</xref><xref ref-type="bibr" rid="article-29850.r64">[64]</xref></p>
        <p>
<bold>Radioactive Iodine (RAI)</bold>
</p>
        <p>RAI (using I-131 isotope) can be the preferred therapy in&#x000a0;most patients, especially the ones with high-risk comorbidities who are at high risk for surgery and need definitive management. Patients who have contraindications for the use of thionamides should also undergo RAI.&#x000a0;This procedure should be avoided in patients planning a pregnancy in the six months due to the risk of inducing hypothyroidism in the fetus. RAI is also contraindicated in lactating women. Patients will a history of moderate to severe Graves orbitopathy should not undergo treatment with RAI due to the risk of worsening eye disease. Patients with underlying thyroid malignancies should not undergo RAI.&#x000a0;</p>
        <p>Radioactive iodine-131&#x000a0;leads to the destruction of thyroid follicular cells.&#x000a0;In a female patient of reproductive age, it is highly recommended to obtain a beta-hCG to rule out pregnancy before initiation of RAI therapy.&#x000a0;Patients on a thionamide (methimazole or propylthiouracil) should be instructed to discontinue this therapy approximately one week before RAI therapy since thionamide administration can interfere with the therapeutic benefit of RAI therapy.&#x000a0;Several months are typically needed status post-RAI therapy to achieve euthyroid status.</p>
        <list list-type="bullet">
          <list-item>
            <p>Graves disease</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>A single fixed dose of 10-15 mCi (370-555 MBq) is sufficient to render a patient with GD hypothyroid. Doses of RAI can be calculated using the size of the thyroid gland and the uptake of RAI. Cure rates are higher with higher doses, up to 85%.<xref ref-type="bibr" rid="article-29850.r65">[65]</xref><xref ref-type="bibr" rid="article-29850.r66">[66]</xref>&#x000a0;</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Toxic multinodular goiter</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>A single dose of 15 mCi is usually sufficient.<xref ref-type="bibr" rid="article-29850.r67">[67]</xref>&#x000a0;A calculated dose of 150-200 microCi (5.5-7.4 MBq) per gram of thyroid tissue can be used, corrected for 24-hour radioactive iodine uptake. Cure rates are 55% at three months and 80% at six months.<xref ref-type="bibr" rid="article-29850.r68">[68]</xref>&#x000a0;Long-term studies have shown that the risk of hypothyroidism after RAI for TMNG is 3-5% by one year, 16% by five years, and 64% by 24 years.<xref ref-type="bibr" rid="article-29850.r69">[69]</xref><xref ref-type="bibr" rid="article-29850.r70">[70]</xref><xref ref-type="bibr" rid="article-29850.r71">[71]</xref></p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Toxic adenoma</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>A single fixed of 10-20 mCi (370-740 MBq) is usually sufficient. The dose can also be calculated based on nodule size: 150-200 microCi (5.5-7.5 MBq).<xref ref-type="bibr" rid="article-29850.r72">[72]</xref>&#x000a0;Long-term studies have shown that the risk of hypothyroidism after RAI for TA is 8% in 1 year and 60% in 20 years.<xref ref-type="bibr" rid="article-29850.r73">[73]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Typically, patients with GD are evaluated in 4 to 6-week intervals with an assessment of TSH, free T4, and total T3 levels. The monitoring should continue for another six months or till the patient becomes hypothyroid and is on a stable dose of levothyroxine. Failure to achieve euthyroidism after RAI therapy may indicate the need for either repeat RAI therapy (for symptomatic hyperthyroidism) or the initiation of thyroxine therapy (for hypothyroidism).</p>
        <p>RAI therapy involves the release of stored thyroid hormone due to the destruction of thyroid follicular cells, leading to transient hyperthyroidism. This is generally well&#x000a0;tolerated, although this transient hyperthyroidism is of concern in patients with significant cardiac disease. For patients with cardiac disease, pretreatment with a thionamide to deplete the stored hormone is recommended to avoid the potential exacerbation of the cardiac disease. In addition, the use of beta-blocker therapy is also essential in these patients to minimize beta-adrenergic symptoms.</p>
        <p>
<bold>Surgery</bold>
</p>
        <p>Preferred in women planning a pregnancy in less than six months, presence of active Graves orbitopathy, patients who experience significant adverse effects with the use of thionamides, when thyroid malignancy is suspected, presence of large compressive goiters, and the presence of co-existing hyperparathyroidism needing surgery. The surgical option should be avoided in patients with significant comorbidities deemed high-risk for undergoing surgery.</p>
        <p>Euthyroidism should be achieved before surgery with the use of thionamides. Preoperative SSKI (saturated solutions of potassium iodide), KI (potassium iodide), or Lugol's iodine should be used in patients with Graves disease and TMNG to decrease gland vascularity and decrease intraoperative blood loss.<xref ref-type="bibr" rid="article-29850.r74">[74]</xref><xref ref-type="bibr" rid="article-29850.r75">[75]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Graves disease:&#x000a0;Near-total or total thyroidectomy is the surgical procedure of choice in patients with Graves disease, with excellent&#x000a0;cure rates. The risk of recurrence or disease persistence with total thyroidectomy is almost 0% versus 8% with sub-total thyroidectomy after five years.<xref ref-type="bibr" rid="article-29850.r76">[76]</xref><xref ref-type="bibr" rid="article-29850.r77">[77]</xref><xref ref-type="bibr" rid="article-29850.r78">[78]</xref></p>
          </list-item>
          <list-item>
            <p>Toxic multinodular goiter: Surgical option of choice is near-total or total thyroidectomy to avoid recurrences.<xref ref-type="bibr" rid="article-29850.r79">[79]</xref><xref ref-type="bibr" rid="article-29850.r80">[80]</xref></p>
          </list-item>
          <list-item>
            <p>Toxic adenoma: Preferred surgical option is ipsilateral thyroid lobectomy or isthmusectomy, with excellent cure rates and a risk of the treatment failure rate of less than 1%.<xref ref-type="bibr" rid="article-29850.r81">[81]</xref></p>
          </list-item>
        </list>
        <p>After patients undergo near-total or total thyroidectomy, they should be started on weight-based levothyroxine replacement therapy (0.8 mcg/lb or 1.6 mcg/kg). Lower doses should be used in the elderly, especially in patients with a history of cardiovascular disease or arrhythmia.</p>
      </sec>
      <sec id="article-29850.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Hyperthyroidism presents with relatively nonspecific signs and symptoms such as palpitations, increased frequency of bowel movements, and weight loss, among others. Therefore, other pathologies should be ruled out as possible explanations for the patient&#x02019;s symptomatology.</p>
        <p>For etiologies of hyperthyroidism, differential diagnoses can be made based on the physical findings of the thyroid gland. Palpation of a normal thyroid gland in the context of&#x000a0;hyperthyroidism can be due to Graves disease, painless thyroiditis, or factitious hyperthyroidism (thyrotoxicosis factitia). Graves disease can also present as a non-tender, enlarged thyroid.</p>
        <p>Palpation of a tender enlarged thyroid may indicate De Quervain thyroiditis (subacute thyroiditis). Palpation of a single thyroid nodule is likely indicative of thyroid adenoma, and palpation of multiple thyroid nodules strongly indicates toxic multinodular goiter.</p>
        <p>Other differential diagnoses include&#x000a0;euthyroid hyperthyroxinemia (in which serum total T4 and T3 are elevated, but the TSH level is within normal limits) and struma&#x000a0;ovarii.</p>
      </sec>
      <sec id="article-29850.s10" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Antithyroid drugs or thionamides are associated with rare but serious adverse effects of agranulocytosis, hepatotoxicity, and vasculitis. Hepatotoxicity is more common with the use of propylthiouracil (2.7%) than methimazole (0.4%).<xref ref-type="bibr" rid="article-29850.r82">[82]</xref>&#x000a0;Hepatotoxicity due to methimazole is more likely to be cholestatic, while hepatotoxicity due to PTU is more likely to be hepatocellular.<xref ref-type="bibr" rid="article-29850.r83">[83]</xref> Hematological complications have an incidence of 0.1-0.15% with the use of PTU or methimazole. Of these patients, 89% had agranulocytosis, and 11% had pancytopenia or aplastic anemia.<xref ref-type="bibr" rid="article-29850.r84">[84]</xref>&#x000a0;Patients taking PTU and rarely methimazole can develop p-ANCA (anti-neutrophil cytoplasmic antibody) positive small vessel vasculitis.<xref ref-type="bibr" rid="article-29850.r85">[85]</xref> Up to 40% of those taking PTU can develop c-ANCA positivity, but very few develop vasculitis.<xref ref-type="bibr" rid="article-29850.r86">[86]</xref><xref ref-type="bibr" rid="article-29850.r87">[87]</xref>&#x000a0;These medications are also associated with the development of drug-induced lupus.<xref ref-type="bibr" rid="article-29850.r88">[88]</xref><xref ref-type="bibr" rid="article-29850.r89">[89]</xref>&#x000a0;Few cases of hypoglycemia secondary to autoimmune insulin syndrome have been reported using methimazole.<xref ref-type="bibr" rid="article-29850.r90">[90]</xref><xref ref-type="bibr" rid="article-29850.r91">[91]</xref></p>
        <p>If patients develop an acute febrile illness with symptoms of pharyngitis, they should get blood work done to check complete blood cell counts along with differentials to rule out the development of agranulocytosis. Liver function tests should be assessed in patients who develop a pruritic rash, abdominal pain or bloating, anorexia, nausea, vomiting,&#x000a0;fatigue, jaundice, light-colored stool, or dark urine.</p>
        <p>The most common complications following total or near-total thyroidectomy include hypocalcemia due to hypoparathyroidism in less than 2% of cases (can be transient or permanent), recurrent or superior laryngeal nerve paralysis in less than 2% of cases (can be temporary or permanent), hemorrhage, and complications related to anesthesia.<xref ref-type="bibr" rid="article-29850.r92">[92]</xref><xref ref-type="bibr" rid="article-29850.r93">[93]</xref><xref ref-type="bibr" rid="article-29850.r94">[94]</xref></p>
      </sec>
      <sec id="article-29850.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Hyperthyroidism secondary to Graves disease or toxic multinodular goiter has overall&#x000a0;good outcomes&#x000a0;due to high success rates of definitive treatment and efficacy of symptom management. However, as with any disease, the prognosis of particular disease pathology is patient-oriented and reflects management, response to therapy, and compliance with prescribed treatments.</p>
      </sec>
      <sec id="article-29850.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Untreated or unmanaged hyperthyroidism can lead to an extreme case of hyperthyroidism, referred to as a thyroid storm. Reflecting the hypermetabolic state of hyperthyroidism, the patient experiencing thyroid storm will present with tachycardia, increased GI motility, diaphoresis, anxiety, fever, and manifestations of multiple organ dysfunction. Thyroid storm is a potentially life-threatening complication of hyperthyroidism, thus requiring immediate attention. The mortality rate is high in individuals more than 60 years of age, of about 16%.<xref ref-type="bibr" rid="article-29850.r95">[95]</xref>&#x000a0;</p>
        <p>Prolonged untreated or undertreated hyperthyroidism is associated with an increased risk of acute cardiovascular events, atrial fibrillation, ischemic stroke, osteoporosis, infertility, abnormalities of menstrual cycles, and mortality.<xref ref-type="bibr" rid="article-29850.r96">[96]</xref><xref ref-type="bibr" rid="article-29850.r97">[97]</xref><xref ref-type="bibr" rid="article-29850.r98">[98]</xref><xref ref-type="bibr" rid="article-29850.r99">[99]</xref>&#x000a0;Subclinical hyperthyroidism has been associated with an increased risk of arrhythmias such as&#x000a0;atrial fibrillation, osteoporosis, hip fractures, and mortality.<xref ref-type="bibr" rid="article-29850.r100">[100]</xref><xref ref-type="bibr" rid="article-29850.r2">[2]</xref><xref ref-type="bibr" rid="article-29850.r101">[101]</xref></p>
      </sec>
      <sec id="article-29850.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education regarding hyperthyroidism is similar to&#x000a0;other diseases. Patients should be educated on the importance of compliance with therapy and on the signs and symptoms of extreme hyperthyroidism (thyroid storm).</p>
      </sec>
      <sec id="article-29850.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Acute coronary syndrome (ACS)&#x000a0;may&#x000a0;be complicated by thyroid dysfunction. A recent study has shown that thyroid dysfunction is seen in up to 23.3% of patients with coronary artery disease and both overt and subclinical hyperthyroidism in 2.5%.<xref ref-type="bibr" rid="article-29850.r102">[102]</xref></p>
        <p>Pregnancy and concurrent thyroid pathology can pose medical management challenges. PTU is recommended in pregnant women presenting with hyperthyroidism due to methimazole&#x02019;s association with congenital defects. Close monitoring is recommended with PTU administration, as overcorrection can potentially cause fetal hypothyroidism. The thyroid hormone is particularly&#x000a0;important due to its role in fetal neurodevelopment. Recent literature indicates that previously recommended TSH cutoffs in pregnant women lead to overcorrection of thyroid disease in pregnant patients.<xref ref-type="bibr" rid="article-29850.r103">[103]</xref>&#x000a0;As fetal exposure to thyroid hormone plays a significant role, careful monitoring and close supervision are&#x000a0;warranted.</p>
        <p>Neonatal thyrotoxicosis results from fetal tissue exposure to excessive thyroid hormone.&#x000a0;There are typically two variants of neonatal thyrotoxicosis: autoimmune-mediated and non-autoimmune-mediated. Autoimmune fetal hyperthyroidism involves the transplacental passage of TSH receptor-stimulating antibodies. Hyperthyroidism is usually transient as symptoms cease 5 to 6 months after birth following clearance of maternal antibodies. Non-autoimmune fetal hyperthyroidism is associated with an activating mutation of either the TSH receptor or the <italic toggle="yes">GNAS</italic> gene (leading to McCune-Albright syndrome). Unlike the autoimmune etiology, the non-autoimmune variant is permanent, long persisting after birth.<xref ref-type="bibr" rid="article-29850.r104">[104]</xref></p>
      </sec>
      <sec id="article-29850.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Except for thyroid storm, hyperthyroidism in itself&#x000a0;is rarely life-threatening but can pose a significant burden on a patient&#x02019;s day-to-day routine. Hyperthyroidism can present with many symptoms and, if not managed, can lead to poor quality of life. Because there are many causes of hyperthyroidism, the condition is best managed by an interprofessional team.</p>
        <p>Primary care&#x000a0;clinicians should educate patients on the importance of medication compliance. In addition, the patient should be informed by the pharmacist that certain products like contrast dyes, expectorants, food supplements, and seaweed tablets may contain high levels of iodine and interfere with therapy.</p>
        <p>Inpatient management of a patient with hyperthyroidism does not always necessarily&#x000a0;require consultation with an endocrinologist. Still,&#x000a0;thyroid storm strongly warrants consultation with an endocrinologist and possible admission to the intensive care unit due to potentially life-threatening complications such as tachycardia and hypertensive crisis. Therefore, nurses and physician assistants involved with patient care should be vigilant about the signs and symptoms of thyroid storm.</p>
        <p>As mentioned, any consideration of RAI therapy in a female of reproductive potential should follow a negative beta-hCG, as pregnancy is an absolute contraindication to RAI therapy. Therefore, incorporating a mandatory pregnancy test into an overall care plan would help avoid potentially damaging radiation exposure.</p>
        <p>Patients with Graves disease will need an ophthalmology consult. For those who undergo thyroidectomy, lifelong treatment with levothyroxine is required. Pharmacists must review prescriptions, check for drug interactions, and educate patients.</p>
        <p>The interprofessional team must communicate with other members to ensure the patient receives the current standard of care treatment.</p>
      </sec>
      <sec id="article-29850.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29850&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29850">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/hormones-and-body-chemistry/hyperthyroidism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29850">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29850/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29850">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-29850.s17">
        <fig id="article-29850.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Evaluation Algorithm, Hyperthyroidism. This image is an&#x000a0;algorithm&#x000a0;to help providers&#x000a0;evaluate patients&#x000a0;presenting with hyperthyroidism. Contributed by J Kaur, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Untitled" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-29850.s18">
        <title>References</title>
        <ref id="article-29850.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Rivkees</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</article-title>
            <source>Thyroid</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>1343</fpage>
            <page-range>1343-1421</page-range>
            <pub-id pub-id-type="pmid">27521067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biondi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Subclinical Hyperthyroidism.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jun</month>
            <day>21</day>
            <volume>378</volume>
            <issue>25</issue>
            <fpage>2411</fpage>
            <page-range>2411-2419</page-range>
            <pub-id pub-id-type="pmid">29924956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Biondi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cosco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nocera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sacc&#x000e0;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Filetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lombardi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perticone</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>85</volume>
            <issue>12</issue>
            <fpage>4701</fpage>
            <page-range>4701-5</page-range>
            <pub-id pub-id-type="pmid">11134131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vadiveloo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Donnan</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Cochrane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leese</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2011</year>
            <month>May</month>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>1344</fpage>
            <page-range>1344-51</page-range>
            <pub-id pub-id-type="pmid">21346066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lindhardsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gislason</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>Nov</month>
            <day>27</day>
            <volume>345</volume>
            <fpage>e7895</fpage>
            <pub-id pub-id-type="pmid">23186910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cappola</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Danese</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kuller</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ladenson</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Thyroid status, cardiovascular risk, and mortality in older adults.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Mar</month>
            <day>01</day>
            <volume>295</volume>
            <issue>9</issue>
            <fpage>1033</fpage>
            <page-range>1033-41</page-range>
            <pub-id pub-id-type="pmid">16507804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Selmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olesen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>von Kappelgaard</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Torp-Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gislason</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>99</volume>
            <issue>7</issue>
            <fpage>2372</fpage>
            <page-range>2372-82</page-range>
            <pub-id pub-id-type="pmid">24654753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Uberti</surname>
                <given-names>ED</given-names>
              </name>
            </person-group>
            <article-title>Iodine excess and hyperthyroidism.</article-title>
            <source>Thyroid</source>
            <year>2001</year>
            <month>May</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>493</fpage>
            <page-range>493-500</page-range>
            <pub-id pub-id-type="pmid">11396708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brucker-Davis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oldfield</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Skarulis</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Doppman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1999</year>
            <month>Feb</month>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>476</fpage>
            <page-range>476-86</page-range>
            <pub-id pub-id-type="pmid">10022404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mittra</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Niederkohr</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>El-Maghraby</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McDougall</surname>
                <given-names>IR</given-names>
              </name>
            </person-group>
            <article-title>Uncommon causes of thyrotoxicosis.</article-title>
            <source>J Nucl Med</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>49</volume>
            <issue>2</issue>
            <fpage>265</fpage>
            <page-range>265-78</page-range>
            <pub-id pub-id-type="pmid">18199610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunzendorfer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>deLas Morenas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalir</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Struma ovarii and hyperthyroidism.</article-title>
            <source>Thyroid</source>
            <year>1999</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>499</fpage>
            <page-range>499-502</page-range>
            <pub-id pub-id-type="pmid">10365682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Scholz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gutierrez-Buey</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lazarus</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dayan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Okosieme</surname>
                <given-names>OE</given-names>
              </name>
            </person-group>
            <article-title>Global epidemiology of hyperthyroidism and hypothyroidism.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2018</year>
            <month>May</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>301</fpage>
            <page-range>301-316</page-range>
            <pub-id pub-id-type="pmid">29569622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Houlden</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Amiodarone-induced thyrotoxicosis: a review.</article-title>
            <source>Can J Cardiol</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>421</fpage>
            <page-range>421-4</page-range>
            <pub-id pub-id-type="pmid">19584973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lazarus</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Lithium and thyroid.</article-title>
            <source>Best Pract Res Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>723</fpage>
            <page-range>723-33</page-range>
            <pub-id pub-id-type="pmid">19942149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illouz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Briet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Rodien</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>171</volume>
            <issue>3</issue>
            <fpage>R91</fpage>
            <page-range>R91-9</page-range>
            <pub-id pub-id-type="pmid">24833135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Blackard</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Akeno</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Interferon alpha treatment and thyroid dysfunction.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>1051</fpage>
            <page-range>1051-66; x-xi</page-range>
            <pub-id pub-id-type="pmid">17983936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guaraldi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>La Selva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sam&#x000e0;</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fierro</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Savoia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arvat</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2018</year>
            <month>May</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>549</fpage>
            <page-range>549-556</page-range>
            <pub-id pub-id-type="pmid">29043574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iddah</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Macharia</surname>
                <given-names>BN</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune thyroid disorders.</article-title>
            <source>ISRN Endocrinol</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>509764</fpage>
            <pub-id pub-id-type="pmid">23878745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearce</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Farwell</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Thyroiditis.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Jun</month>
            <day>26</day>
            <volume>348</volume>
            <issue>26</issue>
            <fpage>2646</fpage>
            <page-range>2646-55</page-range>
            <pub-id pub-id-type="pmid">12826640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Heged&#x000fc;s</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Graves' Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Oct</month>
            <day>20</day>
            <volume>375</volume>
            <issue>16</issue>
            <fpage>1552</fpage>
            <page-range>1552-1565</page-range>
            <pub-id pub-id-type="pmid">27797318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vitti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rago</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tonacchera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinchera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Toxic multinodular goiter in the elderly.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2002</year>
            <volume>25</volume>
            <issue>10 Suppl</issue>
            <fpage>16</fpage>
            <page-range>16-8</page-range>
            <pub-id pub-id-type="pmid">12508907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Vestergaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sigurdsson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland.</article-title>
            <source>J Intern Med</source>
            <year>1991</year>
            <month>May</month>
            <volume>229</volume>
            <issue>5</issue>
            <fpage>415</fpage>
            <page-range>415-20</page-range>
            <pub-id pub-id-type="pmid">2040867</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham-Nordling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bystr&#x000f6;m</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rring</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lantz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calissendorff</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nystr&#x000f6;m</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Jansson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>J&#x000f6;rneskog</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Nystr&#x000f6;m</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ohrling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Orn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hallengren</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wallin</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Incidence of hyperthyroidism in Sweden.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>165</volume>
            <issue>6</issue>
            <fpage>899</fpage>
            <page-range>899-905</page-range>
            <pub-id pub-id-type="pmid">21908653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garmendia Madariaga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Santos Palacios</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guill&#x000e9;n-Grima</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galofr&#x000e9;</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>99</volume>
            <issue>3</issue>
            <fpage>923</fpage>
            <page-range>923-31</page-range>
            <pub-id pub-id-type="pmid">24423323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franklyn</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The management of hyperthyroidism.</article-title>
            <source>N Engl J Med</source>
            <year>1994</year>
            <month>Jun</month>
            <day>16</day>
            <volume>330</volume>
            <issue>24</issue>
            <fpage>1731</fpage>
            <page-range>1731-8</page-range>
            <pub-id pub-id-type="pmid">7910662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heged&#x000fc;s</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bonnema</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bennedbaek</surname>
                <given-names>FN</given-names>
              </name>
            </person-group>
            <article-title>Management of simple nodular goiter: current status and future perspectives.</article-title>
            <source>Endocr Rev</source>
            <year>2003</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>102</fpage>
            <page-range>102-32</page-range>
            <pub-id pub-id-type="pmid">12588812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tunbridge</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Evered</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Appleton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brewis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of thyroid disease in a community: the Whickham survey.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1977</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>6</issue>
            <fpage>481</fpage>
            <page-range>481-93</page-range>
            <pub-id pub-id-type="pmid">598014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanderpump</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Tunbridge</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Appleton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grimley Evans</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tunbridge</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-68</page-range>
            <pub-id pub-id-type="pmid">7641412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hollowell</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Staehling</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Hannon</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Gunter</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>489</fpage>
            <page-range>489-99</page-range>
            <pub-id pub-id-type="pmid">11836274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Quan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Hyperthyroidism Prevalence in China After Universal Salt Iodization.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>651534</fpage>
            <pub-id pub-id-type="pmid">34122333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tomisti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aghini-Lombardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Amiodarone and the thyroid: a 2012 update.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>340</fpage>
            <page-range>340-8</page-range>
            <pub-id pub-id-type="pmid">22433945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Safran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aghini-Lombardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rajatanavin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lenziardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pacchiarotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aronin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Macchia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haffajee</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy.</article-title>
            <source>Ann Intern Med</source>
            <year>1984</year>
            <month>Jul</month>
            <volume>101</volume>
            <issue>1</issue>
            <fpage>28</fpage>
            <page-range>28-34</page-range>
            <pub-id pub-id-type="pmid">6428291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krohn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>F&#x000fc;hrer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eszlinger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brauer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paschke</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Molecular pathogenesis of euthyroid and toxic multinodular goiter.</article-title>
            <source>Endocr Rev</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>504</fpage>
            <page-range>504-24</page-range>
            <pub-id pub-id-type="pmid">15615818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamburger</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Evolution of toxicity in solitary nontoxic autonomously functioning thyroid nodules.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>1980</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-93</page-range>
            <pub-id pub-id-type="pmid">7372787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanbury</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ermans</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bourdoux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oken</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tonglet</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vidor</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Medeiros-Neto</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Iodine-induced hyperthyroidism: occurrence and epidemiology.</article-title>
            <source>Thyroid</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-100</page-range>
            <pub-id pub-id-type="pmid">9492158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bervini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trelle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stettler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trepp</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of Iodine-Induced Hyperthyroidism After Administration of Iodinated Contrast During Radiographic Procedures: A Systematic Review and Meta-Analysis of the Literature.</article-title>
            <source>Thyroid</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>31</volume>
            <issue>7</issue>
            <fpage>1020</fpage>
            <page-range>1020-1029</page-range>
            <pub-id pub-id-type="pmid">33327840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaimal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Iodinated contrast-induced thyrotoxicosis.</article-title>
            <source>CMAJ</source>
            <year>2013</year>
            <month>Feb</month>
            <day>05</day>
            <volume>185</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-7</page-range>
            <pub-id pub-id-type="pmid">23148056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fradkin</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Iodide-induced thyrotoxicosis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1983</year>
            <month>Jan</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-20</page-range>
            <pub-id pub-id-type="pmid">6218369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bogazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Approach to the patient with amiodarone-induced thyrotoxicosis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>2529</fpage>
            <page-range>2529-35</page-range>
            <pub-id pub-id-type="pmid">20525904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahn Chair</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Greenlee</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McDougall</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Montori</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Rivkees</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sosa</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>MN</given-names>
              </name>
              <collab>American Thyroid Association</collab>
              <collab>American Association of Clinical Endocrinologists</collab>
            </person-group>
            <article-title>Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.</article-title>
            <source>Thyroid</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>593</fpage>
            <page-range>593-646</page-range>
            <pub-id pub-id-type="pmid">21510801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x0015e;ahl&#x00131;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nd&#x000fc;z</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Thyroid-associated Ophthalmopathy.</article-title>
            <source>Turk J Ophthalmol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>94</fpage>
            <page-range>94-105</page-range>
            <pub-id pub-id-type="pmid">28405484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartalena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Baldeschi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dayan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Eckstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marcocci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Marin&#x000f2;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wiersinga</surname>
                <given-names>WM</given-names>
              </name>
              <collab>EUGOGO &#x02020;</collab>
            </person-group>
            <article-title>The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2021</year>
            <month>Aug</month>
            <day>27</day>
            <volume>185</volume>
            <issue>4</issue>
            <fpage>G43</fpage>
            <page-range>G43-G67</page-range>
            <pub-id pub-id-type="pmid">34297684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bahn</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Graves' ophthalmopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Feb</month>
            <day>25</day>
            <volume>362</volume>
            <issue>8</issue>
            <fpage>726</fpage>
            <page-range>726-38</page-range>
            <pub-id pub-id-type="pmid">20181974</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fatourechi</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Pretibial myxedema: pathophysiology and treatment options.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2005</year>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>295</fpage>
            <page-range>295-309</page-range>
            <pub-id pub-id-type="pmid">16252929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jadidi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sigari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Efendizade</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grigorian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lehto</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kolla</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Thyroid acropachy: A rare skeletal manifestation of autoimmune thyroid disease.</article-title>
            <source>Radiol Case Rep</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>917</fpage>
            <page-range>917-919</page-range>
            <pub-id pub-id-type="pmid">31193617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fatourechi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>5435</fpage>
            <page-range>5435-41</page-range>
            <pub-id pub-id-type="pmid">12466333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Leo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Braverman</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Hyperthyroidism.</article-title>
            <source>Lancet</source>
            <year>2016</year>
            <month>Aug</month>
            <day>27</day>
            <volume>388</volume>
            <issue>10047</issue>
            <fpage>906</fpage>
            <page-range>906-918</page-range>
            <pub-id pub-id-type="pmid">27038492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Favresse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burlacu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Maiter</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gruson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm.</article-title>
            <source>Endocr Rev</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>39</volume>
            <issue>5</issue>
            <fpage>830</fpage>
            <page-range>830-850</page-range>
            <pub-id pub-id-type="pmid">29982406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Radulescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Root</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karger</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Killeen</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sokoll</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Burmeister</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Sep</month>
            <day>26</day>
            <volume>318</volume>
            <issue>12</issue>
            <fpage>1150</fpage>
            <page-range>1150-1160</page-range>
            <pub-id pub-id-type="pmid">28973622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peyerl</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>TSI assay utilization: impact on costs of Graves' hyperthyroidism diagnosis.</article-title>
            <source>Am J Manag Care</source>
            <year>2012</year>
            <month>Jan</month>
            <day>01</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-14</page-range>
            <pub-id pub-id-type="pmid">22435785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Autilio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Locantore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pontecorvi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zuppi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrozza</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Stimulating TSH receptor autoantibodies immunoassay: analytical evaluation and clinical performance in Graves' disease.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>55</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <page-range>172-177</page-range>
            <pub-id pub-id-type="pmid">28388869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahaly</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Bioassays for TSH Receptor Antibodies: Quo Vadis?</article-title>
            <source>Eur Thyroid J</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-5</page-range>
            <pub-id pub-id-type="pmid">25960955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baek</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>DG</given-names>
              </name>
              <collab>Korean Society of Thyroid Radiology (KSThR)</collab>
              <collab>Korean Society of Radiology</collab>
            </person-group>
            <article-title>Clinical applications of Doppler ultrasonography for thyroid disease: consensus statement by the Korean Society of Thyroid Radiology.</article-title>
            <source>Ultrasonography</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>315</fpage>
            <page-range>315-330</page-range>
            <pub-id pub-id-type="pmid">32892523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daniels</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Amiodarone-induced thyrotoxicosis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>86</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">11231968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>A 2011 survey of clinical practice patterns in the management of Graves' disease.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>12</issue>
            <fpage>4549</fpage>
            <page-range>4549-58</page-range>
            <pub-id pub-id-type="pmid">23043191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balazs</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Le&#x000f6;vey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>The immunosuppressive effect of methimazole on cell-mediated immunity is mediated by its capacity to inhibit peroxidase and to scavenge free oxygen radicals.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-16</page-range>
            <pub-id pub-id-type="pmid">3024872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lechpammer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lukac</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lechpammer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kusi&#x00107;</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Antithyroid drug-induced immunomodulation in Graves' disease patients.</article-title>
            <source>Acta Med Croatica</source>
            <year>2002</year>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-6</page-range>
            <pub-id pub-id-type="pmid">12455450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laurberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk?</article-title>
            <source>Eur J Endocrinol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>171</volume>
            <issue>1</issue>
            <fpage>R13</fpage>
            <page-range>R13-20</page-range>
            <pub-id pub-id-type="pmid">24662319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hackmon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Blichowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The safety of methimazole and propylthiouracil in pregnancy: a systematic review.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>34</volume>
            <issue>11</issue>
            <fpage>1077</fpage>
            <page-range>1077-1086</page-range>
            <pub-id pub-id-type="pmid">23231846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years later.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>12</day>
            <volume>179</volume>
            <issue>5</issue>
            <fpage>R261</fpage>
            <page-range>R261-R274</page-range>
            <pub-id pub-id-type="pmid">30320502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Treatment of hyperthyroid disease.</article-title>
            <source>Ann Intern Med</source>
            <year>1994</year>
            <month>Aug</month>
            <day>15</day>
            <volume>121</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-8</page-range>
            <pub-id pub-id-type="pmid">7518659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohlin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Filipsson Nystr&#x000f6;m</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Eliasson</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000-2010.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>170</volume>
            <issue>3</issue>
            <fpage>419</fpage>
            <page-range>419-27</page-range>
            <pub-id pub-id-type="pmid">24366943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Komiya</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kouki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nishimori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takasu</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Remission and recurrence of hyperthyroid Graves' disease during and after methimazole treatment when assessed by IgE and interleukin 13.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>8</issue>
            <fpage>3540</fpage>
            <page-range>3540-4</page-range>
            <pub-id pub-id-type="pmid">11502776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Noh</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Yoshimura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mikura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kinoshita</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mitsumatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoshiyama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fukushita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshihara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sugino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Does Age or Sex Relate to Severity or Treatment Prognosis in Graves' Disease?</article-title>
            <source>Thyroid</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>1409</fpage>
            <page-range>1409-1415</page-range>
            <pub-id pub-id-type="pmid">33882721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allahabadia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daykin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sheppard</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gough</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Franklyn</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>8</issue>
            <fpage>3611</fpage>
            <page-range>3611-7</page-range>
            <pub-id pub-id-type="pmid">11502786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Santos</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Romaldini</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (&#x000b9;&#x000b3;&#x000b9;I) doses for Graves disease treatment.</article-title>
            <source>Clin Nucl Med</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-4</page-range>
            <pub-id pub-id-type="pmid">22310249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roque</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Pilli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dalmazio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Castagna</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>105</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">32320467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>van Heerden</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): surgery versus radioiodine.</article-title>
            <source>Surgery</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>132</volume>
            <issue>6</issue>
            <fpage>916</fpage>
            <page-range>916-23; discussion 923</page-range>
            <pub-id pub-id-type="pmid">12490836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Lundell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Israelsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dahlqvist</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism.</article-title>
            <source>J Nucl Med</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-7</page-range>
            <pub-id pub-id-type="pmid">7057248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akaishi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Uruno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okuwa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shibuya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nagahama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy.</article-title>
            <source>Ann Nucl Med</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>10</issue>
            <fpage>749</fpage>
            <page-range>749-54</page-range>
            <pub-id pub-id-type="pmid">21971604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nygaard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heged&#x000fc;s</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ulriksen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Radioiodine therapy for multinodular toxic goiter.</article-title>
            <source>Arch Intern Med</source>
            <year>1999</year>
            <month>Jun</month>
            <day>28</day>
            <volume>159</volume>
            <issue>12</issue>
            <fpage>1364</fpage>
            <page-range>1364-8</page-range>
            <pub-id pub-id-type="pmid">10386513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reschini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Paracchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of the autonomous thyroid nodule: a review.</article-title>
            <source>Eur J Endocrinol</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>135</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-90</page-range>
            <pub-id pub-id-type="pmid">8921817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ceccarelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bencivelli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grasso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pinchera</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>331</fpage>
            <page-range>331-5</page-range>
            <pub-id pub-id-type="pmid">15730415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erbil</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozluk</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Giri&#x0015f;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salmaslioglu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Issever</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Barbaros</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kapran</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozarma&#x0011f;an</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tezelman</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>92</volume>
            <issue>6</issue>
            <fpage>2182</fpage>
            <page-range>2182-9</page-range>
            <pub-id pub-id-type="pmid">17389702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ansaldo</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Pretolesi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Varaldo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Minuto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borgonovo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Derchi</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter.</article-title>
            <source>J Am Coll Surg</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>191</volume>
            <issue>6</issue>
            <fpage>607</fpage>
            <page-range>607-12</page-range>
            <pub-id pub-id-type="pmid">11129808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Si</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>5</issue>
            <fpage>739</fpage>
            <page-range>739-46</page-range>
            <pub-id pub-id-type="pmid">23521078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Limonard</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Bisschop</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Fliers</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nieveen van Dijkum</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Thyroid function after subtotal thyroidectomy in patients with Graves' hyperthyroidism.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>548796</fpage>
            <pub-id pub-id-type="pmid">22448136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Adhami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Snaith</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Krukowski</surname>
                <given-names>ZH</given-names>
              </name>
            </person-group>
            <article-title>Changing trends in surgery for Graves' disease: a cohort comparison of those having surgery intended to preserve thyroid function with those having ablative surgery.</article-title>
            <source>J Otolaryngol Head Neck Surg</source>
            <year>2013</year>
            <month>May</month>
            <day>29</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">23718902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dogan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Karaman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Ozaslan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Atalay</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Total thyroidectomy for the surgical treatment of multinodular goiter.</article-title>
            <source>Surg Today</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>323</fpage>
            <page-range>323-7</page-range>
            <pub-id pub-id-type="pmid">21365410</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hisham</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Total thyroidectomy: the procedure of choice for toxic goitre.</article-title>
            <source>Asian J Surg</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>59</fpage>
            <page-range>59-62</page-range>
            <pub-id pub-id-type="pmid">18490216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidal-Trecan</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Eckman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis.</article-title>
            <source>Thyroid</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>11</issue>
            <fpage>933</fpage>
            <page-range>933-45</page-range>
            <pub-id pub-id-type="pmid">15671772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otsuka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Noh</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mukasa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taniyama</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Hepatotoxicity and cutaneous reactions after antithyroid drug administration.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>310</fpage>
            <page-range>310-5</page-range>
            <pub-id pub-id-type="pmid">22332800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>619</fpage>
            <page-range>619-29</page-range>
            <pub-id pub-id-type="pmid">25279406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakamura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Miyauchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Miyawaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Imagawa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>98</volume>
            <issue>12</issue>
            <fpage>4776</fpage>
            <page-range>4776-83</page-range>
            <pub-id pub-id-type="pmid">24057289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noh</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Noguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mukasa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nihojima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>8</issue>
            <fpage>2806</fpage>
            <page-range>2806-11</page-range>
            <pub-id pub-id-type="pmid">19491223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HY</given-names>
              </name>
            </person-group>
            <article-title>The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism.</article-title>
            <source>Endocr Res</source>
            <year>2004</year>
            <month>May</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-13</page-range>
            <pub-id pub-id-type="pmid">15473130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazisiz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ong&#x000fc;t</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Terzio&#x0011f;lu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karayal&#x000e7;in</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment.</article-title>
            <source>Int J Clin Pract</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>19</fpage>
            <page-range>19-24</page-range>
            <pub-id pub-id-type="pmid">18284438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aloush</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Litinsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Caspi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elkayam</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-9</page-range>
            <pub-id pub-id-type="pmid">16887463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hess</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Drug-related lupus.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>Jun</month>
            <day>02</day>
            <volume>318</volume>
            <issue>22</issue>
            <fpage>1460</fpage>
            <page-range>1460-2</page-range>
            <pub-id pub-id-type="pmid">3259288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomez Cruz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Jabbar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Severe hypoglycemia secondary to&#x000a0;methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male.</article-title>
            <source>Pediatr Diabetes</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>652</fpage>
            <page-range>652-5</page-range>
            <pub-id pub-id-type="pmid">22759245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Savani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kadaria</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Methimazole-induced insulin autoimmune syndrome.</article-title>
            <source>Ther Adv Endocrinol Metab</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>178</fpage>
            <page-range>178-81</page-range>
            <pub-id pub-id-type="pmid">27540463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Avenia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bernante</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De Palma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gulino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nasi</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Pelizzo</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pezzullo</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years.</article-title>
            <source>World J Surg</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-6</page-range>
            <pub-id pub-id-type="pmid">14961204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the morbidity and complications of total thyroidectomy.</article-title>
            <source>Arch Otolaryngol Head Neck Surg</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>389</fpage>
            <page-range>389-92</page-range>
            <pub-id pub-id-type="pmid">11926912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safioleas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stamatakos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rompoti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mouzopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iannescu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Salichou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Skandalakis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Complications of thyroid surgery.</article-title>
            <source>Chirurgia (Bucur)</source>
            <year>2006</year>
            <season>Nov-Dec</season>
            <volume>101</volume>
            <issue>6</issue>
            <fpage>571</fpage>
            <page-range>571-81</page-range>
            <pub-id pub-id-type="pmid">17283832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiyagarajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Platzbecker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ittermann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>V&#x000f6;lzke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Haug</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Estimating Incidence and Case Fatality of Thyroid Storm in Germany Between 2007 and 2017: A Claims Data Analysis.</article-title>
            <source>Thyroid</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>11</issue>
            <fpage>1307</fpage>
            <page-range>1307-1315</page-range>
            <pub-id pub-id-type="pmid">36006371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dekkers</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Horv&#x000e1;th-Puh&#x000f3;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cannegieter</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Vandenbroucke</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>176</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">27697972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrahamsen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Laulund</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nybo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Brix</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Heged&#x000fc;s</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis.</article-title>
            <source>J Bone Miner Res</source>
            <year>2015</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>898</fpage>
            <page-range>898-905</page-range>
            <pub-id pub-id-type="pmid">25431028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mintziori</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Duntas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goulis</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Consequences of hyperthyroidism in male and female fertility: pathophysiology and current management.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>849</fpage>
            <page-range>849-53</page-range>
            <pub-id pub-id-type="pmid">26956000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siu</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Pong</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Jim</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Kung</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism.</article-title>
            <source>Heart Rhythm</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-73</page-range>
            <pub-id pub-id-type="pmid">19187905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effect of subclinical hyperthyroidism on osteoporosis: A meta-analysis of cohort studies.</article-title>
            <source>Endocrine</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-48</page-range>
            <pub-id pub-id-type="pmid">32207036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collet</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Gussekloo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>den Elzen</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Cappola</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Balmer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Iervasi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>&#x000c5;svold</surname>
                <given-names>BO</given-names>
              </name>
              <name>
                <surname>Sgarbi</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>V&#x000f6;lzke</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gencer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maciel</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Molinaro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bremner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Luben</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Maisonneuve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cornuz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Khaw</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Westendorp</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Franklyn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Vittinghoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rodondi</surname>
                <given-names>N</given-names>
              </name>
              <collab>Thyroid Studies Collaboration</collab>
            </person-group>
            <article-title>Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.</article-title>
            <source>Arch Intern Med</source>
            <year>2012</year>
            <month>May</month>
            <day>28</day>
            <volume>172</volume>
            <issue>10</issue>
            <fpage>799</fpage>
            <page-range>799-809</page-range>
            <pub-id pub-id-type="pmid">22529182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdulaziz Qari</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Thyroid Hormone Profile in Patients With Acute Coronary Syndrome.</article-title>
            <source>Iran Red Crescent Med J</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>e26919</fpage>
            <pub-id pub-id-type="pmid">26421178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korevaar</surname>
                <given-names>TIM</given-names>
              </name>
              <name>
                <surname>Medici</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Visser</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Thyroid disease in pregnancy: new insights in diagnosis and clinical management.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>10</issue>
            <fpage>610</fpage>
            <page-range>610-622</page-range>
            <pub-id pub-id-type="pmid">28776582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29850.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samuels</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Namoc</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Neonatal Thyrotoxicosis.</article-title>
            <source>Clin Perinatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-40</page-range>
            <pub-id pub-id-type="pmid">29406005</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
